Description
To mitigate risks in early-stage peptide therapeutics discovery, CD ComputaBio offers a comprehensive Peptide Drug Target Validation Service. We combine structural biology modeling with advanced computational workflows to systematically evaluate the druggability, binding pockets, and interaction mechanisms of potential peptide-drug targets. Through molecular docking, interface residue analysis, and predictive binding affinity profiling, this service helps clients confidently confirm target-peptide compatibility before initiating expensive in vitro or in vivo screening.